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The prevalence of asthma and allergic disease has increased in many countries, and there has been
speculation that immunization promotes allergic sensitization. Bordetella pertussis infection exacerbates aller-
gic asthmatic responses. We investigated whether acellular pertussis vaccine (Pa) enhanced or prevented B.
pertussis-induced exacerbation of allergic asthma. Groups of mice were immunized with Pa, infected with B.
pertussis, and/or sensitized to ovalbumin. Immunological, pathological, and physiological changes were mea-
sured to assess the impact of immunization on immune deviation and airway function. We demonstrate that
immunization did not enhance ovalbumin-specific serum immunoglobulin E production. Histopathological
examination revealed that immunization reduced the severity of airway pathology associated with sensitization
in the context of infection and decreased bronchial hyperreactivity upon methacholine exposure of infected and
sensitized mice. These data demonstrate unequivocally the benefit of Pa immunization to health and justify
selection of Pa in mass vaccination protocols. In the absence of infection, the Pa used in this study enhanced
the interleukin-10 (IL-10) and IL-13 responses and influenced airway hyperresponsiveness to sensitizing
antigen; however, these data do not suggest that Pa contributes to childhood asthma overall. On the contrary,
wild-type virulent B. pertussis is still circulating in most countries, and our data suggest that the major
influence of Pa is to protect against the powerful exacerbation of asthma-like pathology induced by B. pertussis.
The prevalence of asthma and allergic disease has increased
in many countries (5, 14), and there has been speculation as to
the possible causes (4, 46, 47), including a possible role of
immunization in promoting allergic sensitization (12, 55).
Asthma is a chronic disease of the respiratory tract and is
tightly associated with airway hyperresponsiveness, increased
mucus production, and infiltration of the bronchial mucosa by
CD4 T cells (59). In allergic asthma there is evidence of an
altered local T-cell response in favor of Th2 cytokines (inter-
leukin-4 [IL-4], IL-5, and IL-13), which results in B-cell isotype
switching to immunoglobulin E (IgE); mast cell, eosinophil,
and basophil recruitment; and the production of a wide range
of inflammatory mediators (61).
Epidemiological and clinical studies have provided intrigu-
ing data that suggest that a link exists between the relative lack
of infectious diseases and the increase in allergic disorders (9,
56, 57); this is referred to as the “hygiene hypothesis.” Accord-
ing to this hypothesis, viral and bacterial infections prevent the
induction of allergen-specific Th2 cells because they establish
Th1-biased immunity. In particular, the prenatal period and
early childhood are considered critical intervals for the estab-
lishment of a putative Th1-Th2 balance. On the other hand,
several studies have suggested that viral and bacterial infec-
tions exacerbate asthma. For example, respiratory syncytial
virus, commonly associated with pulmonary infections in in-
fancy, is known to exacerbate asthma (24, 30), and recently, we
have shown that Bordetella pertussis infection exacerbates al-
lergic asthma in a murine ovalbumin (OVA) model (8).
B. pertussis is a gram-negative bacterium and the causative
agent of pertussis, or whooping cough, a respiratory disease
that remains a significant cause of morbidity and mortality
among infants worldwide. It is a highly contagious disease and
can occur at any age, although severe illness is more common
in young unimmunized children. B. pertussis infection induces
Th1 responses in humans and can be modeled by respiratory
challenge of mice, in which the response correlates well to the
responses in humans (36).
There has been speculation about the possible promotion of
allergy by common childhood vaccines (21, 43). A number of
studies have analyzed the prevalence of allergic sensitization
and atopic disease in relation to immunization (12, 21). Gruber
et al. (12) found that children with higher levels of immuniza-
tion coverage seemed to acquire transient protection against
the development of atopy in the first years of life. In contrast,
Hurwitz and Morgenstern (21) suggested that immunization
against diphtheria-pertussis-tetanus appeared to be associated
with an increased risk of subsequent asthma or other allergies.
Two different types of pertussis vaccine have been used in
infant immunization programs. The whole-cell pertussis vac-
cine (Pw) consists of heat- and formalin-inactivated virulent
whole bacteria, whereas the acellular pertussis vaccine (Pa) is
composed of purified components of the bacteria, typically
including inactivated pertussis toxin (PT). Immunization with
Pw has a high degree of efficacy and is associated with the
induction of antigen-specific Th1 cells (27, 28, 53), but it has
been associated with reactogenicity (3). In contrast, immuni-
zation with Pa induces Th2 responses in children and in murine
models (2), but it has reduced reactogenicity (6, 34). It has
been suggested that the promotion of allergy may occur di-
rectly by administering potentially proallergic vaccines or indi-
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rectly by hindering the Th1-promoting effects of infectious
agents. Pertussis vaccine acts as an adjuvant for antigen-spe-
cific responses in laboratory animals (45); active PT, known to
enhance immunoglobulin E (IgE) formation in animal models
(26), is widely used as an adjuvant in animal experiments to
enhance the immune response to coadministered antigens (51)
and has been linked with a shift toward Th2-like cytokine
production in humans (39, 48).
We have previously shown that infection with B. pertussis
modulates allergen priming and the severity of airway pathol-
ogy in a murine model of allergic asthma (8). Furthermore, we
have demonstrated that Th1-inducing Pw protects against ex-
acerbation of allergic asthma due to B. pertussis (7). In order to
test whether immunization with Pa exacerbated asthma, we
used a well-characterized murine model of acellular pertussis
vaccination and B. pertussis infection in combination with the
murine OVA model of airway hyperresponsiveness. Our find-
ings demonstrate that a Th2-inducing Pa does not enhance but
protects against exacerbation of allergic asthma due to B. per-
tussis. However, we note that in the absence of B. pertussis
infection, a Pa can enhance IL-13 expression under certain
conditions.
MATERIALS AND METHODS
Animals. Female BALB/c (age, 6 to 8 weeks; Harlan, Bicester, Oxon, United
Kingdom) mice were used under the guidelines of the Irish Department of
Health and the research ethics committee of the National University of Ireland,
Maynooth. The BALB/c strain was selected because the performance of pertussis
vaccines in this strain has been shown to correlate well with the performance of
the vaccines in clinical trials with humans (37) and allergic asthma in this strain
has been shown to be consistent with previous models of allergic asthma (8).
Immunization and airway delivery of OVA. Four groups of at least 35 6- to
8-week-old female BALB/c mice were immunized intraperitoneally (i.p.) with
0.16 IU of Pa [The Candidate International Reference Material for Purified
(Acellular) Pertussis Vaccine, 1997, National Institute for Biological Standards
and Control, Potters Bar, United Kingdom], equivalent to 1/25 of the human
dose, according to the schedule outlined in Table 1. The four groups consisted of
mice immunized with Pa (group Pa); mice challenged with virulent B. pertussis
via aerosol and immunized with Pa (group PaBp); mice immunized with Pa and
sensitized with OVA (group PaOVA); and mice immunized with Pa, challenged
with virulent B. pertussis via aerosol, and sensitized with OVA (group PaBpOVA).
At day 0 the mice were infected with B. pertussis; selected groups were then
sensitized with OVA. Sensitization involved 100 g of OVA (grade V; Sigma,
Dorchester, United Kingdom) emulsified in 2% Alhydrogel adjuvant (Superfos
Biosector, Kvistgaard, Denmark) administered i.p. on days 10 and 24. The
control group received saline alone (i.p.). On days 35, 36, and 37, PaOVA- and
PaBpOVA-sensitized mice received 50 g of OVA intranasally (i.n.), whereas
the remaining groups received saline only (Table 1). All experiments were re-
peated twice.
Aerosol infection. Respiratory infection was initiated by aerosol challenge with
B. pertussis strain W28, following growth under agitation conditions at 37°C in
Stainer-Scholte liquid medium. Bacteria from a log-phase culture were resus-
pended at a concentration of 2  1010 CFU/ml in 1% (wt/vol) casein in 0.9%
(wt/vol) saline. The challenge inoculum was administered to groups of mice on
day 0 (the group challenged with virulent B. pertussis via aerosol [group Bp],
PaBp, and PaBpOVA). Administration was by aerosol exposure over a period of
15 min with a nebulizer. Groups of four or more mice were killed at various time
points after aerosol challenge to assess the number of viable B. pertussis organ-
isms in the lungs. The remaining mice received a similar aerosol of sterile saline
alone.
Enumeration of viable bacteria in the lungs. Lungs were removed aseptically
and placed into 1 ml of sterile physiological saline with 1% casein. One hundred
microliters of serially diluted homogenate from individual lungs was placed onto
triplicate Bordet-Gengou agar plates, and the number of CFU was determined
after incubation at 37°C for 4 days. The results are reported as the mean number
of B. pertussis CFU for individual lungs determined in triplicate for lungs from
four or more mice per time point. All experiments were repeated twice.
Measurement of OVA- and B. pertussis-specific antibody concentrations. Total
and OVA-specific IgE concentrations were measured by using a rat anti-mouse
IgE monoclonal antibody (BD, Pharmingen, San Diego, Calif.). The IgE con-
centration was expressed in micrograms per milliliter after comparison to the
concentrations of murine IgE standards.
Cytokine measurement from BALF specimen and spleen cell cultures. Bron-
choalveolar lavage fluid (BALF) specimens were obtained by repeat administra-
tion and aspiration of 0.5-ml volumes (total, 5 ml) of phosphate-buffered saline
via cannulation of the trachea of mice from three experiments (n  5 mice per
treatment group on each occasion). Spleen cells (2  106/ml) from infected,
sensitized, and control mice (n  4 or more mice per group on each occasion)
were cultured with heat-inactivated B. pertussis (1  104 CFU/ml), OVA (20
g/ml), concanavalin A (5 g/ml; positive control), or medium alone (negative
control). At 72 h, culture supernatants were sampled for cytokine analysis;
although the kinetics of cytokine production varies at this time point, this time
point has previously proved acceptable for the detection of most cytokines (19).
Concentrations of IL-5, IL-10, IL-13, and gamma interferon (IFN-) from spleen
tissue and BALF samples were assessed by an enzyme-linked immunosorbent
assay (BD, Pharmingen). Cytokine concentrations were calculated by compari-
son with cytokine standards of known concentration, as described previously (29).
Whole-body plethysmography. Airway responsiveness was assessed by metha-
choline (MCh)-induced airflow obstruction in conscious mice by the use of
whole-body plethysmography (Buxco Electronics, Sharon, Conn.), as described
previously (16). Pulmonary airflow obstruction was measured by enhanced
pause, a value that is determined from the ratio of the expiratory time and
TABLE 1. Experimental design
Description (group name)a
Procedure on the following day (route of administration):
42 14 0 10 24 35, 36, 37
Pa Pa Pa Saline aerosol Saline (i.p.) Saline (i.p. and i.n.) Saline (i.n.)
Pa and B. pertussis infection (PaBp) Pa Pa B. pertussis aerosol infection Saline (i.p.) Saline (i.p. and i.n.) Saline (i.n.)
Pa and OVA sensitization (PaOVA) Pa Pa Saline aerosol OVA (i.p.) OVA (i.p. and i.n.) OVA (i.n.)
Pa, B. pertussis infection, and OVA
sensitization (PaBpOVA)
Pa Pa B. pertussis aerosol infection OVA (i.p.) OVA (i.p. and i.n.) OVA (i.n.)
Control Saline aerosol Saline (i.p.) Saline (i.p. and i.n.) Saline (i.n.)
B. pertussis infection (Bp) B. pertussis aerosol infection Saline (i.p.) Saline (i.p. and i.n.) Saline (i.n.)
OVA sensitization (OVA) Saline aerosol OVA (i.p.) OVA (i.p. and i.n.) OVA (i.n.)
B. pertussis infection and OVA
sensitization (BpOVA)
B. pertussis aerosol infection OVA (i.p.) OVA (i.p. and i.n.) OVA (i.n.)
a Groups of female BALB/c mice (age, 6 to 8 weeks) were immunized (i.p.) and boosted with Pa on days 42 and 14. Mice were either sham infected or infected
with B. pertussis (Bp) by aerosol exposure. On day 10 and subsequently, selected groups were sensitized to OVA by the i.p. and i.n. routes. Bacterial burdens were
measured between days 0 and 37. All other readouts were on day 37. For comparison, further groups of mice were treated as follows: control mice were sham infected
on day 0 and sham sensitized. A second group (group Bp) was infected with B. pertussis on day 0 and sham sensitized. The third group (group OVA) was sham infected
but sensitized with OVA (100 g i.p.) on days 10 and 24 and then again (50 g i.n.) on days 24, 35, 36, and 37. A separate group (group BpOVA) was infected with
B. pertussis on day 0 and sensitized as described above. Each experiment was repeated at least twice, with n  35 mice per group on each occasion.
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relaxation time to the peak expiratory flow and peak inspiratory flow and that is
thought to correlate with airway responsiveness. Measurements were obtained
after exposure of mice to phosphate-buffered saline (baseline) for 3 min, fol-
lowed by the delivery of incremental doses (3.3 to 50 mg/ml) of MCh by aerosol (16).
Respiratory tract histology. Animals (n  5 mice per group per experiment)
were killed on day 37. Lungs were removed; fixed in a paraformaldehyde-lysine-
periodate fixative; embedded in paraffin; sectioned; and stained by the hematox-
ylin-eosin, Discombes (for identification of eosinophils), Alcian blue (for iden-
tification of mucus), periodic acid-Schiff (for assessment of basement membrane
thickness), azure A (for identification of mast cells), and Van Gieson (for iden-
tification of fibrosis) methods. The histopathological changes that were evident
were graded according to a semiquantitative scoring system as mild, moderate, or
severe by two researchers without prior knowledge of the treatment group. All
experiments were performed at least twice (n  5) on each occasion.
Statistical methods. Results are expressed as the means  standard errors of
the means (SEMs) for the indicated number of animals. Student’s t test was used
to determine significance among the groups in cytokine assays, whereas two-way
analysis of variance was used for plethysmography. A P value of 	0.05 was
considered significant. Analyses were performed with Prism software (Graph-
Pad, San Diego, Calif.).
RESULTS
OVA sensitization does not impair Pa-mediated clearance of
B. pertussis. Both Pa immunization and OVA sensitization
induce powerful Th2 responses in mice (15, 27, 50), whereas B.
pertussis infection induces strong Th1 responses in mice and
children (37, 52). The goal of this study was to examine the
possibility that Pa immunization enhances allergic sensitiza-
tion; however, it was also necessary to examine the confound-
ing influence of sensitizing antigen upon clearance. Therefore,
the effect of OVA sensitization upon the development of a
protective response to infection in Pa-immunized and nonim-
munized mice was examined. Mice received combinations of
OVA sensitization, Pa immunization, and aerosol challenge
with virulent B. pertussis (Table 1). Groups of mice infected
with B. pertussis (groups Bp and BpOVA) showed similar ki-
netics of bacterial clearance (Fig. 1), indicating that OVA
sensitization did not measurably influence the kinetics of bac-
terial clearance. Likewise, OVA-sensitized and nonsensitized
mice that had been immunized prior to bacterial challenge
(groups PaBpOVA and PaBp, respectively) showed identical
rates of clearance. No bacteria were recovered from the unin-
fected OVA-sensitized group or the control group (Fig. 1). The
bacterial burden in the infected groups (groups Bp and
BpOVA) peaked at day 10 and declined thereafter. Pa-immu-
nized mice cleared subsequent infection by B. pertussis by day
7. In contrast, only unimmunized mice (groups Bp and
BpOVA) showed complete bacterial clearance by day 35 (Fig.
1). Therefore, sensitization with OVA did not impair the vac-
cine-mediated clearance of B. pertussis in this model.
Pa immunization does not enhance OVA-specific IgE pro-
duction. The goal of this study was to examine the influence of
Pa immunization on responses associated with allergic sensiti-
zation. Although OVA-induced sensitization does not impair
vaccine-mediated clearance of B. pertussis, it was possible that
Pa influenced allergic sensitization. An increase in the concen-
trations of IgE antibodies specific for PT, a component of Pa,
has been reported in other studies (40, 50). Therefore, the
serum IgE responses of mice sensitized to OVA following Pa
or sham immunization were examined. Differences were ob-
served in the induction of IgE antibodies to the different an-
tigens, with the concentration of OVA-specific IgE typically
being greater than the concentration of IgE induced to B.
pertussis (Fig. 2A and B). Pa induced little B. pertussis-specific
IgE, and this was not altered by OVA sensitization (Fig. 2A).
The only increase in B. pertussis-specific IgE was observed
when a combination of immunization and infection prior to
OVA sensitization was used. This resulted in a small but sig-
nificant increase in the B. pertussis-specific IgE concentration
detected (group PaBpOVA compared to groups PaOVA,
BpOVA, and PaBp, P  0.0026, 0.001, and 0.004, respectively)
(Fig. 2A).
OVA sensitization induced high levels of OVA-specific IgE,
as reported previously (8). Notably, Pa did not enhance the
OVA-specific IgE response (Fig. 2B). It has been shown that
Pw immunization of mice down-modulates the OVA-specific
IgE response (7); however, Pa did not have this effect in this
model: OVA-specific IgE was not significantly reduced by prior
Pa immunization (groups OVA and Pa OVA) (Fig. 2B). In
contrast, a combination of immunization and infection prior to
OVA sensitization (group PaBpOVA) resulted in a significant
reduction in the OVA-specific IgE titer compared to that in
mice sensitized to OVA in the absence or the presence of Pa
immunization (groups OVA and PaOVA, respectively, for
which P 0.0447 and 0.0413, respectively), similar to the effect
previously reported (8) for infection in combination with OVA
sensitization (group BpOVA) (Fig. 2B).
Pa immunization enhances OVA-induced IL-10 and IL-13.
It has been shown previously (8) that B. pertussis infection
enhances the OVA-induced IL-10 and IL-13 detectable in
BALF specimens and from spleen cell cultures stimulated with
specific antigen. Pa immunization is known to induce Th2
cytokines (1, 52), although its effect on IL-13 production is
unknown. In order to dissect the influence of immunization on
airway hyperresponsiveness, cell-mediated immune responses
were examined in spleen cell preparations from the various
study groups. Pa immunization alone or in combination with B.
pertussis infection (group Pa or PaBp) induced very little IL-10,
FIG. 1. Course of B. pertussis infection in experimental and control
mice. Groups of mice were killed at various intervals after challenge,
and the number of viable bacteria was estimated by performing colony
counts on individual lung homogenates. Results are representative of
those from at least two experiments and are presented as the mean
number of CFU in the lungs, determined individually for the lungs
from four or more mice per group at each time point. Data for the
control and OVA groups have been offset from zero for clarity. Ctrl,
control group.
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IL-13, or IFN- (Fig. 3). This was consistent with the protec-
tion observed earlier (Fig. 1) and previous data (28). Pa im-
munization in combination with OVA (group PaOVA) in-
duced significantly higher levels of IL-10 (P  0.001), IL-13 (P
 0.007), and IFN- (P  0.006) (Fig. 3A to D) than OVA
sensitization alone, but no differences in IL-5 levels were de-
tected. In contrast, a combination of immunization and infec-
tion prior to OVA sensitization (group PaBpOVA) resulted in
a significant reduction of IL-5, IL-10, and IL-13 levels (P 
0.0014, 0.0012, and 0.0158, respectively) compared to those in
group PaOVA (Fig. 3A to C).
To extend these findings, we examined the levels of cyto-
kines present in BALF specimens from each group of mice. Pa
immunization alone induced no detectable IFN- in BALF
specimens, but low levels of IL-5, IL-10, and IL-13 were re-
producibly detected (Fig. 4A to D). As expected, OVA sensi-
tization induced IL-10 and IL-13 and very high levels of IL-5
(Fig. 4A-C); OVA sensitization also induced airway IFN-, as
has been reported previously (8). Pa immunization influenced
the levels of cytokines detected in sensitized mice (group
PaOVA), reducing the levels of IL-5 and IFN- (P 0.008 and
P  0.0015, respectively, compared to those in mice sensitized
with OVA alone; Fig. 4A and D, respectively) but significantly
increasing the levels of IL-10 (P  0.001) and IL-13 (P 
0.002) (Fig. 4B and C, respectively). PaBpOVA mice also
showed reduced IL-5 and IFN- levels but increased IL-10 and
IL-13 levels compared to those in mice sensitized with OVA
alone, although this effect was less pronounced than that seen
in mice in group PaOVA (Fig. 4A to D).
Pa immunization protects against B. pertussis exacerbation
of bronchial hyperresponsiveness and pathology but influ-
ences sensitization to OVA. It has been proposed that prior
Th1 responses to bacterial infections protect against allergic
disease; however, Th1-inducing B. pertussis infection exacer-
bates airway hyperresponsiveness in OVA-sensitized mice (8).
We have shown previously that prior immunization with a
whole-cell pertussis vaccine, which induces a very similar im-
mune response to B. pertussis, did not enhance but protected
against the airway hyperresponsiveness exacerbated by B. per-
tussis (7). In the present study we examined the influence of Pa
immunization on physiological lung function using whole-body
plethysmography to measure enhanced pause, a surrogate
marker associated with airway hyperreactivity. Statistical anal-
ysis by two-way analysis of variance showed that Pa-immunized
mice and/or mice challenged with B. pertussis (groups Pa, Bp,
and PaBp) showed airway hyperreactivity comparable to that
of the controls (Fig. 5A and B). As expected, mice sensitized to
OVA showed significantly increased airway hyperreactivity
compared to that of the controls (P 	 0.0003) (Fig. 5A and C).
As demonstrated above, B. pertussis infection (group BpOVA)
exacerbated the OVA-induced response (P 0.0008 for group
BpOVA compared to mice sensitized to OVA) (Fig. 5D). The
most notable influence of Pa immunization was that it signif-
icantly reduced this exacerbation (for group PaBpOVA versus
group BpOVA, P  0.048; Fig. 5D). Thus, Pa protects against
the enhanced airway reactivity induced by the combination of
infection and sensitization seen in mice in group BpOVA.
Given that Pa influences airway IL-10 and IL-13 levels, we
were also interested in observing the influence of Pa on OVA-
sensitized mice in the absence of infection. Immunization did
influence bronchial hyperreactivity upon OVA sensitization,
but this increase was only evident at high concentrations of
MCh exposure (Fig. 5C).
B. pertussis infection is known to modulate the quality of the
OVA-induced inflammatory influx to the respiratory tract, with
a marked reduction in eosinophil numbers accompanied by
various degrees of epithelial hyperplasia, mucus metaplasia,
and airway pathology (8). Lung tissue from experimental mice
was assessed histologically (Table 2). Minimal pathology was
observed in mice immunized with Pa or those immunized and
infected with B. pertussis (group PaBp) (Table 2 and Fig. 6A
and B). Pa-immunized and OVA-sensitized mice (group
PaOVA) illustrated moderate mural and periairway inflamma-
tion with accompanying mild epithelial hyperplasia and
smooth-muscle hypertrophy (Fig. 6C). The combination of Pa
FIG. 2. Serum IgE elicited by Pa vaccination, bacterial infection, and
allergic sensitization. The B. pertussis-specific (A) or OVA-specific (B) se-
rum IgE responses elicited from each experimental group are shown.
The experimental groups included mice receiving combinations of immu-
nization with Pa (groups Pa, PaBp, PaOVA, and PaBpOVA), infection
with B. pertussis (groups Bp, PaBp, BpOVA, and PaBpOVA), or sen-
sitization to OVA (groups OVA, PaOVA, and PaBpOVA). Controls
(Ctrl) were sham immunized, sham infected, or sham sensitized with
saline, as appropriate. Results are expressed as the mean antibody
concentrations  SEMs. Mice that were infected only (group Bp)
made no OVA-specific IgE, and mice that were sensitized only (group
OVA) made no pertussis-specific IgE. The data presented are repre-
sentative of those from two experiments; in each case, at least four
animals were assessed, and each individual assessment was performed
independently in triplicate. , significantly greater IgE induction than
that by mice in groups PaOVA, BpOVA, and PaBp (P 0.0026, 0.001,
and 0.004, respectively); , significantly less IgE induction by mice in
group PaBpOVA than by mice in groups OVA and PaOVA (P 
0.0447 and 0.0413, respectively). Data for group BpOVA are included
here for comparison.
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immunization, B. pertussis infection, and OVA sensitization
induced a similar degree of airway inflammation, but with
accompanying mild mucous metaplasia, moderate epithelial
hyperplasia, and smooth-muscle hypertrophy (Fig. 6D). In
summary, the pathology associated with immunized and sen-
sitized mice (group PaOVA) was not greater than that seen in
nonimmunized mice (group OVA), and Pa immunization
(group PaBpOVA) protected against the exacerbated pathol-
ogy seen in infected and sensitized mice (group BpOVA).
DISCUSSION
The present study demonstrates that Pa immunization pro-
tects against B. pertussis exacerbation of OVA-induced airway
hyperresponsiveness in a murine model of allergic asthma. Pa
immunization did not enhance OVA-specific IgE production
but did enhance OVA-induced IL-10 and IL-13 in the absence
of infection. Nevertheless, Pa immunization did not enhance
the observed airway pathology over that seen in nonimmunized
and sensitized mice. Furthermore, Pa immunization protected
against the exacerbated pathology seen in infected, sensitized
mice. Taken together, these results suggest that the major
influence of Pas is not to promote allergic asthma but, rather,
to protect against the exacerbating influence of virulent B.
pertussis infection.
Pertussis vaccination in infancy has been discussed as a pu-
tative risk factor for bronchial asthma (18, 41, 49), presumably
through Th2-mediated mechanisms. Th2 responses are
thought to be protective against parasite-mediated disease (60)
but are associated with allergic disorders (59, 61). It has been
suggested that induction of Th2 cells or failure to mount a Th1
or regulatory T-cell response to foreign antigens in childhood
may enhance atopic disease (10, 49). It is therefore conceivable
that changing patterns of microbial exposure through infection
and vaccination in childhood may contribute to the observed
increase in atopic disease and asthma. Active PT enhances IgE
responses to foreign antigens and is widely used as an adjuvant
in animal experiments to enhance the immune responses to
coadministered antigens (26, 51). Inactivated PT is a compo-
nent of most Pas, and it is known that booster immunization of
children with an acellular pertussis vaccine enhanced Th2 cy-
tokine production and serum IgE responses against PT (50).
Circulating IgE antibodies against PT have also been found
after primary immunization with Pa with or without a subse-
quent Pa or Pw booster (11, 17, 42). Furthermore, B. pertussis
infection is known to modulate allergen priming and exacer-
bates the severity of allergen-driven pathology in a murine
model (8); however, Th1-inducing vaccines (Pw) protect
against this (7). In the present study we show that Pa immu-
nization did not enhance the OVA-specific IgE response (Fig.
2B); this suggests that Pa-like vaccines are unlikely to promote
atopy and is consistent with the findings of studies of Pa-
immunized children, which found no significant enhancement
FIG. 3. Cell-mediated immune responses from the spleen elicited by Pa immunization, bacterial infection, and allergic sensitization. The IL-5
(A), IL-10 (B), IL-13 (C), and IFN- (D) responses from spleen cell cultures stimulated with medium alone (negative control [Ctrl]; open bars),
heat-inactivated B. pertussis equivalent to 104 CFU/ml (bars with horizontal shading), OVA (bars with hatched shading), or concanavalin A
(positive control; closed bars) are shown. Responses are representative of duplicate experiments, each of which was performed in triplicate with
individual samples from at least four mice per group and are expressed as means  standard errors. , decreased IL-5 recall response to OVA
compared to that of the PaOVA group (P  0.0014); , significantly increased IL-10 response to OVA compared to that of the PaBpOVA group
(P  0.0012) or the OVA group (P  0.001); , significantly increased IL-13 response to OVA compared to that of the PaBpOVA group (P 
0.0158) or the OVA group (P 0.007); , significantly increased IFN- response to OVA compared to that of OVA-sensitized mice (P 0.006
for mice in group PaOVA; P  0.0056 for mice in group PaBpOVA).
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of IgE specific to third-party antigens (50). Significantly de-
creased levels of OVA-specific IgE were observed in mice in
group PaBpOVA compared to those in either the PaOVA or
the OVA group (Fig. 2B). These data are consistent with our
previous findings (8) that suggest that the mechanism by which
virulent B. pertussis infection exacerbates asthma is indepen-
dent of IgE. Furthermore, this indicates that the major action
of Th2-inducing Pa vaccines is likely protective rather than a
contributor to the exacerbation of asthma.
Airway reactivity can be mediated by IgE-independent
mechanisms that include a direct influence of IL-4 and IL-13
on airway cells (22, 23, 38, 58). It has previously been proposed
(62) that IL-10 plays an essential role in countering such re-
sponses by inducing regulatory T-cell responses, evidence that
suggests that allergic asthma is a disease of defective T-cell
regulation. Interestingly, McGuirk and colleagues (31–33)
have shown that filamentous hemagglutinin, a component of
the acellular vaccine used in this study, has the net effect of
inhibiting the induction, activation, and recruitment of Th1
cells and also interacts with dendritic cells to promote the
production of IL-10. Our findings of elevated IL-10 levels in
BALF specimens support this observation. However, it has
been demonstrated recently (25) that IL-10 can induce IL-13
expression in vivo and that this is responsible for the mucus,
but not the inflammatory or fibrotic effects, observed in the
airways of allergen-sensitized animals. In the present study, we
show that Pa immunization prior to OVA sensitization signif-
icantly increases both IL-10 and IL-13 levels at the systemic
and local levels (Fig. 3A to D and Fig. 4A to D) and that this
may influence airway hyperreactivity (Fig. 5). This is also con-
sistent with the findings of McGuirk and Mills (32) concerning
filamentous hemagglutinin. Although IL-10 can act as an im-
mune regulator, our findings suggest that IL-10 has broader
functions that may contribute to inflammatory disease (8, 13).
This may be through direct effects on the smooth muscle in
damaged airways (13) or indirectly via induction of IL-13 (25).
Although the Pa used in this study enhanced the levels of IL-10
and IL-13 production in response to the sensitizing antigen, the
influences of these cytokines appear to be the greatest in the
context of the widespread airway epithelial damage that occurs
during breakdown of the epithelial-mesenchymal unit (20).
Thus, although Pa induces these cytokines, because its major
influence is to reduce bacterial carriage and, hence, pathology,
the dramatic exacerbating influence on airway hyperreactivity
associated with IL-13 and IL-10 induction by B. pertussis com-
ponents during infection (8) was not observed here. Neverthe-
less, components that do not induce either IL-10 or IL-13
should be considered in enhanced future formulations of Pas.
A study by Gruber et al. (12) revealed no evidence for an
allergy-promoting effect of common childhood vaccines in a
prospectively monitored atopy risk-enhanced birth cohort.
Moreover, children with better vaccination coverage seemed to
FIG. 4. Pa immunization modulates the local cytokine response to B. pertussis infection and OVA sensitization. Diluted BALF specimens from
five mice per group were pooled, and the concentrations of IL-5 (A), IL-10 (B), IL-13 (C), and IFN- (D) were determined by enzyme
immunoassay. The results are representative of those from duplicate experiments, each measurement was performed in triplicate, and the values
are expressed as means  SEMs. , reduced IL-5 concentration compared to that in OVA-sensitized mice (P  0.008 for group PaOVA; P 
0.0025 for group PaBpOVA); , increased IL-10 concentration compared to that in OVA-sensitized mice (P 0.001 for group PaOVA; P 0.001
for group PaBpOVA); , increased IL-13 concentration compared to that in OVA-sensitized mice (P  0.002 for group PaOVA; P  0.022 for
group PaBpOVA); , decreased IFN- concentration compared to that in OVA-sensitized mice (P  0.0015 for group PaOVA; P  0.0026
for group PaBpOVA). Ctrl, controls.
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be better protected against the development of atopy in their
second and third years of life. In particular, immunizations
against measles and mumps, pertussis, and diphtheria and
against tetanus were associated with a transient reduction of
atopy, whereas immunization against polio and Haemophilus
influenzae had no effect (12). A conflicting study of the effects
of vaccination on allergies among children in the United States
has reported that diphtheria-tetanus-pertussis vaccination ap-
peared to increase the risk of allergies and related respiratory
symptoms (21). One contentious interpretation of that study is
that vaccine components may be responsible for a portion of
the increased prevalence of asthma and allergies in U.S. chil-
dren. However, a large number of previous studies have dem-
onstrated that Pa protects against the devastating and some-
times fatal childhood disease whooping cough (27, 44, 50, 54)
and that current commercial formulations of Pa show greatly
reduced reactogenicities compared to that of Pw (6). The latter
data unequivocally demonstrate the benefit of Pa immuniza-
tion to health and justify the selection of Pa for mass vaccina-
tion protocols. Our data do not suggest that Pa contributes to
childhood asthma overall. On the contrary, wild-type virulent
B. pertussis is still circulating in many countries, and our data
suggest that the major influence of Pa is to protect against the
powerful exacerbation of asthma-like pathology induced by B.
pertussis.
We have established models that allow examination of the
mechanisms of interaction between protective immunization
and allergic sensitization. These are based on BALB/c mice,
FIG. 5. Influence of Pa immunization on bronchial hyperresponsiveness. Airway hyperreactivity in response to increasing concentrations of
inhaled MCh was measured by whole-body plethysmography in control (Ctrl; sham infected) or Bp-infected mice (A), mice in group Pa or PaBp
(B), mice in group OVA or PaOVA (C), and mice in group BpOVA or PaBpOVA (D). Results are representative of those from two experiments
(n  4 or more), and values are expressed as the mean enhanced pause  SEM.
TABLE 2. Histological assessment of airway pathologya
Treatment group
Mucous
metaplasia of
airway
epithelium
Hyperplasia
of airway
epithelium
Smooth-muscle
hypertrophy of
airway wall
Periairway or vascular inflammationb
Overall
degree E N L M F
Control         
Bp         
OVA    I   M  
BpOVA    I   M  
Pa         
PaBp         
PaOVA    I   M  
PaBpOVA    I   M  
a A semiquantitative score (, absent; , mild; , moderate; , severe) was assigned to the features of the airway pathology observed.
b Periairway or vascular inflammation was assessed in terms of overall degree; numbers of infiltrating eosinophils (E), neutrophils (N), lymphocytes, plasma cells, and
macrophages (L), and mast cells (M); and circumscribing fibrosis (F). Superscript I, inflammation extending into surrounding pulmonary interstitium and alveolar
spaces; superscript M, macrophage giant cells form part of the inflammatory exudates within surrounding alveolar spaces.
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but qualitatively similar results are seen with alternative strains
(2, 35). While we find evidence that Pa contributes to the
induction of airway IL-13, we demonstrate that the main in-
fluence of acellular pertussis vaccination on asthma is to pro-
tect against the exacerbating effects of virulent B. pertussis
infection.
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